{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:56:42Z","timestamp":1792828602237,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1038\/s41574-024-00976-y","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T14:05:33Z","timestamp":1710943533000},"page":"314-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0127-6482","authenticated-orcid":false,"given":"Sunita M. C.","family":"De Sousa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair K.","family":"Jukes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Candy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Torpy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brindha","family":"Shivalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter-John","family":"Wormald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Santoreneos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"976_CR1","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn, S. et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat. Rev. Endocrinol. 19, 722\u2013740 (2023).","journal-title":"Nat. Rev. Endocrinol."},{"key":"976_CR2","doi-asserted-by":"publisher","first-page":"dgz076","DOI":"10.1210\/clinem\/dgz076","volume":"105","author":"SMC De Sousa","year":"2020","unstructured":"De Sousa, S. M. C. et al. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J. Clin. Endocrinol. Metab. 105, dgz076 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"976_CR3","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/EO-21-0038","volume":"2","author":"SMC De Sousa","year":"2022","unstructured":"De Sousa, S. M. C. Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management? Endocr. Oncol. 2, R31\u2013R50 (2022).","journal-title":"Endocr. Oncol."},{"key":"976_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam, M. P., Molitch, M. E., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485\u2013534 (2006).","journal-title":"Endocr. Rev."},{"key":"976_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(82)92756-8","volume":"2","author":"AM Landolt","year":"1982","unstructured":"Landolt, A. M., Keller, P. J., Froesch, E. R. & Mueller, J. Bromocriptine: Does it jeopardise the result of later surgery for prolactinomas? Lancet 2, 657\u2013658 (1982).","journal-title":"Lancet"},{"key":"976_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1530\/EJE-21-0293","volume":"185","author":"B Baussart","year":"2021","unstructured":"Baussart, B. et al. Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study. Eur. J. Endocrinol. 185, 783\u2013791 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"976_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","volume":"14","author":"M Menucci","year":"2011","unstructured":"Menucci, M., Qui\u00f1ones-Hinojosa, A., Burger, P. & Salvatori, R. Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14, 68\u201374 (2011).","journal-title":"Pituitary"},{"key":"976_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12022-019-09587-0","volume":"30","author":"SMC De Sousa","year":"2019","unstructured":"De Sousa, S. M. C. et al. The genomic landscape of sporadic prolactinomas. Endocr. Pathol. 30, 318\u2013328 (2019).","journal-title":"Endocr. Pathol."},{"key":"976_CR9","doi-asserted-by":"publisher","first-page":"e349","DOI":"10.1016\/j.wneu.2021.07.035","volume":"154","author":"K Wright","year":"2021","unstructured":"Wright, K. et al. Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis. World Neurosurg. 154, e349\u2013e369 (2021).","journal-title":"World Neurosurg."},{"key":"976_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05604-y","volume":"22","author":"IM Zandbergen","year":"2021","unstructured":"Zandbergen, I. M. et al. The PRolaCT studies - a study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma. Trials 22, 653 (2021).","journal-title":"Trials"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-00976-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-00976-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-00976-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:28:34Z","timestamp":1713281314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-00976-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["976"],"URL":"https:\/\/doi.org\/10.1038\/s41574-024-00976-y","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"20 March 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}